CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
复制标题
CXCL9 作为早期肺腺癌患者的预后炎症标志物
DOI：
10.3389/fonc.2020.01049
复制
发表时间：
2020-06
影响因子：
4.7
通讯作者：
Han Baohui
中科院分区：
文献类型：
--
作者：
Zhang Yanwei;Sun Beibei;Hu Minjuan;Lou Yuqing;Lu Jun;Zhang Xueyan;Wang Huimin;Qian Jialin;Chu Tianqing;Han Baohui
背景资料：本研究旨在评价炎症生物标志物在预测早期（IA-IIB期）肺腺癌预后中的价值。方法：在接受切除术的早期肺腺癌患者中，使用基于Luminex珠的测定法检测10种炎症生物标志物。结果：共分析了152例早期肺腺癌患者。患者平均年龄（SD）为59.9（9.4）岁。总体而言，58.6%的患者为女性，从不吸烟者占84.0%。相对于低CXCL 9水平的患者，高CXCL 9水平的肺腺癌患者的复发风险降低了71%（HR = 0.29，95%CI：0.13-0.64，p = 0.0021）。在Bonferroni校正后，CXCL 9仍然与早期肺腺癌复发的风险显著相关。相对于CXCL 9水平低的患者，CXCL 9水平高的肺腺癌患者的死亡风险降低了80（HR = 0.20，95% CI：0.05-0.78，p = 0.021），TCGA验证队列中的患者死亡风险降低29%（HR = 0.71，95% CI：0.45-0.99，p = 0.044）。结论：我们的研究结果首次证明，CXCL 9水平是早期肺腺癌患者无病生存期（DFS）和总生存期（OS）的保护因素。
Background: This study was performed to evaluate the value of inflammatory biomarkers in predicting the prognosis of early-stage (stage IA-IIB) lung adenocarcinoma. Methods: Ten inflammatory biomarkers were tested with a Luminex bead-based assay in early-stage lung adenocarcinoma patients who underwent resection. Results: A total of 152 early-stage lung adenocarcinoma patients were analyzed in this study. The mean patient age (SD) was 59.9 (9.4) years. In total, 58.6% of patients were females, and never smokers accounted for 84.0%. Lung adenocarcinoma patients with high CXCL9 levels had a 71% reduced risk of recurrence relative to patients with low CXCL9 levels (HR = 0.29, 95% CI: 0.13–0.64, p = 0.0021). After Bonferroni correction, CXCL9 remained significantly related to the risk of early-stage lung adenocarcinoma recurrence. Lung adenocarcinoma patients with high CXCL9 levels had an 80% reduced risk of death relative to patients with low CXCL9 levels (HR = 0.20, 95% CI: 0.05–0.78, p = 0.021), and those in the TCGA validation cohort were at a 29% reduced risk of death (HR = 0.71, 95% CI: 0.45–0.99, p = 0.044). Conclusion: Our results demonstrate for the first time that the CXCL9 level is a protective factor for both disease-free survival (DFS) and overall survival (OS) in early-stage lung adenocarcinoma patients.
登录
查看更多内容
DOI：
10.3410/f.725757738.793528485
发表时间：
2017-02
期刊：
--
影响因子：
--
作者：
P. Schil
通讯作者：
P. Schil
DOI：
10.1891/9780826121646.0002
发表时间：
2018-09
期刊：
Cancer Rehabilitation
影响因子：
--
作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
通讯作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
影响因子：
6.4
作者：
Zhang, Yanwei;Xu, Jianlin;Han, Baohui
通讯作者：
Han, Baohui
DOI：
10.4135/9781412963947.n57
发表时间：
2020-02
期刊：
Definitions
影响因子：
--
作者：
P. Woratanarat
通讯作者：
P. Woratanarat
影响因子：
10.3
作者：
Pine, Sharon R.;Mechanic, Leah E.;Harris, Curtis C.
通讯作者：
Harris, Curtis C.